Novo Nordisk has formed a strategic partnership with OpenAI to accelerate drug discovery and enhance AI use across its operations. The collaboration aims to analyze complex data faster, identify promising drug candidates, and shorten development timelines to bring treatments to patients more quickly. The partnership also includes applying AI in manufacturing, supply chain, and corporate functions, with pilot programs launching soon and broader integration by 2026. Additionally, OpenAI will help upskill Novo Nordisk's workforce in AI literacy to maximize technology benefits.
The European Commission has approved Novo Nordisk's Wegovy pill, the first oral GLP-1 receptor agonist for weight management across the EU. This approval covers adults with obesity or overweight with related health issues and follows positive clinica...
The global blood glucose monitoring system market, valued at $16.8 billion in 2025, is projected to grow to $39.4 billion by 2035 at an 8.9% CAGR. Growth is fueled by rising diabetes prevalence, advancements in AI-enabled monitoring devices, and incr...
Vivani Medical is developing a semaglutide implant aimed at improving long-term adherence to GLP-1 treatments like Wegovy and Ozempic, which help with obesity and diabetes. The implant, designed to be replaced biannually or annually, could reduce sid...
